TrianglePUBLICATIONS · 22493413
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2012 May 10
- First author
- Pettitt AR
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Pettitt AR
- type
- Author
- name
- Jackson R
- type
- Author
- name
- Carruthers S
- type
- Author
- name
- Dodd J
- type
- Author
- name
- Dodd S
- type
- Author
- name
- Oates M
- type
- Author
- name
- Johnson GG
- type
- Author
- name
- Schuh A
- type
- Author
- name
- Matutes E
- type
- Author
- name
- Dearden CE
- type
- Author
- name
- Catovsky D
- type
- Author
- name
- Radford JA
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Pettitt AR
- type
- Author
- name
- Jackson R
- type
- Author
- name
- Carruthers S
- type
- Author
- name
- Dodd J
- type
- Author
- name
- Dodd S
- type
- Author
- name
- Oates M
- type
- Author
- name
- Johnson GG
- type
- Author
- name
- Schuh A
- type
- Author
- name
- Matutes E
- type
- Author
- name
- Dearden CE
- type
- Author
- name
- Catovsky D
- type
- Author
- name
- Radford JA
- type
- Author
- bibliography ids
- nci-bib-d60ebc15c206131ef453e456
- book metadata
- content sha256
- ca8ab5afb38d4165b1939a67cc09da45e19502e658f8d54db2b156bdbbd3f897
- document type
- citation
- dois
- 10.1200/JCO.2011.35.9695
- electronic publication date
- display
- 2012 Apr 9
- precision
- day
- year
- 2012
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:22493413
- immutable id
- pubmed:22493413@ca8ab5afb38d4165b1939a67cc09da45e19502e658f8d54db2b156bdbbd3f897
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 14
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 1647-55
- volume
- 30
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 22493413
- provenance
- batch id
- c95be1d0b8cf19942816
- provider
- NCBI PubMed ESummary
- record sha256
- fabe51df6ed681fe275d258536762376757197236d8b6d2965207ecb1620f565
- response sha256
- a96bb680a8f3690267e009557d1b07aab71455ba44aeba18695d98a3eeb5fcf2
- retrieved at
- 2026-09-09T23:46:47.691937+00:00
- publication date
- display
- 2012 May 10
- precision
- day
- year
- 2012
- publication types
- Clinical Trial
- Clinical Trial, Phase II
- Comparative Study
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Preserved source evidence · Not medical advice